FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044910514> ?p ?o ?g. }

• W2044910514 endingPage "53" @default.
• W2044910514 startingPage "41" @default.
• W2044910514 abstract "Over the past 20 years, combined treatment with radiotherapy and second-generation chemotherapy drugs was extensively studied in patients with locally advanced NSCLC and became the standard over radiotherapy alone in patients with good performance status. Radiosensitizing properties of cisplatin have been identified in the laboratory. Close temporal administration of cisplatin and radiation is mandatory for enhanced antitumor efficacy, but results in significant toxicity to normal tissues. Early clinical studies demonstrated that the concurrent administration of cisplatin during STD-RT was feasible, with acceptable esophageal toxicity, and had the potential of significantly improving locoregional control. Carboplatin administered concurrently with accelerated HFX-RT was responsible for a higher rate of esophageal toxicity. Further improvement in survival also requires an effective treatment of micro-metastatic disease through full-dose delivery of cytotoxic drugs and the addition of at least one more active drug in conjunction with cisplatin and radiotherapy to further improve locoregional control of the disease. In most clinical studies, etoposide was the second drug of choice because of its own radiosensitizing properties and possible synergy with cisplatin. In numerous phase II studies, concurrent radiotherapy and PE resulted in reproducible results in terms of local control (30%-40%), median survival (15-18 months), survival at 2 years (35%-40%), and survival at 5 years (25%-30%). In phase III studies, these results were shown to be superior to radiotherapy alone and to induction chemotherapy followed by STD-RT. The question of the potential benefit of HFX-RT combined with PE has been addressed in phase II and III studies. At this time, there is no firm evidence that concurrent chemotherapy with HFX-RT is superior to concurrent chemotherapy with STD-RT in terms of local control and survival. Only a significant benefit in terms of local control or survival would justify the significant increase of esophageal toxicity observed with HFX-RT, which remains the main limiting factor of concurrent chemoradiotherapy with PE. Studies on postinduction surgery after concurrent chemoradiotherapy have been of major interest, demonstrating that a complete pathologic response rate of 25% to 30% could be achieved with a relatively low dose of radiation (45 Gy) and that downstaging was a major determinant for improved long-term survival. Long-term survival after trimodality treatment, however, does not appear to be significantly different from what can be achieved with concurrent chemoradiotherapy alone in phase II studies. Whether postinduction surgery is beneficial to patients with histologically proved stage III (N2) and stage IIIB patients was the question addressed in a large, recently completed phase III intergroup trial and of which the results are eagerly awaited. Over the past 10 years, further progress in radiation technology has been accomplished through three-dimensional treatment planning, multileaf collimators, and electronic portal imaging devices, leading to high-precision conformal radiotherapy and dose escalation and (it is hoped) to improved local control. Intensity-modulated radiotherapy and respiratory gating remain to be evaluated. Accurate delineation of critical organs and pretreatment analysis of toxicity-predicting factors allow for better protection of normal intrathoracic tissues such as lung and esophagus and, it is hoped, will lead to a significant reduction in the incidence of radiation esophagitis and pneumonitis. Third-generation drugs such as taxanes, vinorelbine, and gemcitabine have demonstrated high response rates in NSCLC patients with favorable toxicity profiles. These drugs have also shown major radiosensitizing properties in the laboratory and in the clinical setting, often leading, however, to excessive radiosensitization and unacceptable normal tissue toxicities when administered at full dose concurrently with radiotherapy. Weekly administration of these drugs at reduced doses during a full course of conformational radiotherapy up to 70 Gy or more, however, resulted in encouraging results in several phase II studies, with median survival in excess of 20 months and 2- and 3-year survival rates near 50% and 40%, respectively. The respective benefits of either induction or consolidation full-dose chemotherapy with these drugs, before or after concurrent chemoradiotherapy with second- or third-generation chemotherapy, are presently being evaluated in phase III studies. As a result of improved survival and enhanced local control, most of these studies show a significant increase in the incidence of brain metastases. Because the brain is often the first site of relapse after concurrent chemoradiotherapy with or without surgery, the issue of prophylactic cranial irradiation is currently being addressed in a phase III trial." @default.
• W2044910514 created "2016-06-24" @default.
• W2044910514 creator A5077032150 @default.
• W2044910514 date "2004-02-01" @default.
• W2044910514 modified "2023-09-27" @default.
• W2044910514 title "Radiotherapy and chemotherapy in locally advanced non–small cell lung cancer: preclinical and early clinical data" @default.
• W2044910514 cites W1817196311 @default.
• W2044910514 cites W1831241863 @default.
• W2044910514 cites W1870429510 @default.
• W2044910514 cites W1883860222 @default.
• W2044910514 cites W1930978022 @default.
• W2044910514 cites W1944220675 @default.
• W2044910514 cites W1973641691 @default.
• W2044910514 cites W1986794774 @default.
• W2044910514 cites W1995289673 @default.
• W2044910514 cites W2000476840 @default.
• W2044910514 cites W2005750330 @default.
• W2044910514 cites W2015998684 @default.
• W2044910514 cites W2016431754 @default.
• W2044910514 cites W2018799991 @default.
• W2044910514 cites W2026074901 @default.
• W2044910514 cites W2026097725 @default.
• W2044910514 cites W2026788229 @default.
• W2044910514 cites W2031833724 @default.
• W2044910514 cites W2032034907 @default.
• W2044910514 cites W2035705526 @default.
• W2044910514 cites W2063277014 @default.
• W2044910514 cites W2065333550 @default.
• W2044910514 cites W2090704952 @default.
• W2044910514 cites W2108215214 @default.
• W2044910514 cites W2135257379 @default.
• W2044910514 cites W2138310931 @default.
• W2044910514 cites W2142764975 @default.
• W2044910514 cites W2151900394 @default.
• W2044910514 cites W2159997815 @default.
• W2044910514 cites W2167984282 @default.
• W2044910514 cites W2226077283 @default.
• W2044910514 cites W2244027820 @default.
• W2044910514 cites W2312703485 @default.
• W2044910514 cites W2314730953 @default.
• W2044910514 cites W2317448174 @default.
• W2044910514 cites W2018102666 @default.
• W2044910514 doi "https://doi.org/10.1016/s0889-8588(03)00138-2" @default.
• W2044910514 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15005280" @default.
• W2044910514 hasPublicationYear "2004" @default.
• W2044910514 type Work @default.
• W2044910514 sameAs 2044910514 @default.
• W2044910514 citedByCount "36" @default.
• W2044910514 countsByYear W20449105142012 @default.
• W2044910514 countsByYear W20449105142013 @default.
• W2044910514 countsByYear W20449105142014 @default.
• W2044910514 countsByYear W20449105142015 @default.
• W2044910514 countsByYear W20449105142016 @default.
• W2044910514 countsByYear W20449105142018 @default.
• W2044910514 countsByYear W20449105142019 @default.
• W2044910514 countsByYear W20449105142020 @default.
• W2044910514 countsByYear W20449105142021 @default.
• W2044910514 countsByYear W20449105142022 @default.
• W2044910514 countsByYear W20449105142023 @default.
• W2044910514 crossrefType "journal-article" @default.
• W2044910514 hasAuthorship W2044910514A5077032150 @default.
• W2044910514 hasConcept C126322002 @default.
• W2044910514 hasConcept C143998085 @default.
• W2044910514 hasConcept C2776256026 @default.
• W2044910514 hasConcept C2776694085 @default.
• W2044910514 hasConcept C2777292972 @default.
• W2044910514 hasConcept C2778119113 @default.
• W2044910514 hasConcept C2778239845 @default.
• W2044910514 hasConcept C2781451048 @default.
• W2044910514 hasConcept C29730261 @default.
• W2044910514 hasConcept C31760486 @default.
• W2044910514 hasConcept C509974204 @default.
• W2044910514 hasConcept C71924100 @default.
• W2044910514 hasConceptScore W2044910514C126322002 @default.
• W2044910514 hasConceptScore W2044910514C143998085 @default.
• W2044910514 hasConceptScore W2044910514C2776256026 @default.
• W2044910514 hasConceptScore W2044910514C2776694085 @default.
• W2044910514 hasConceptScore W2044910514C2777292972 @default.
• W2044910514 hasConceptScore W2044910514C2778119113 @default.
• W2044910514 hasConceptScore W2044910514C2778239845 @default.
• W2044910514 hasConceptScore W2044910514C2781451048 @default.
• W2044910514 hasConceptScore W2044910514C29730261 @default.
• W2044910514 hasConceptScore W2044910514C31760486 @default.
• W2044910514 hasConceptScore W2044910514C509974204 @default.
• W2044910514 hasConceptScore W2044910514C71924100 @default.
• W2044910514 hasIssue "1" @default.
• W2044910514 hasLocation W20449105141 @default.
• W2044910514 hasLocation W20449105142 @default.
• W2044910514 hasOpenAccess W2044910514 @default.
• W2044910514 hasPrimaryLocation W20449105141 @default.
• W2044910514 hasRelatedWork W1502181122 @default.
• W2044910514 hasRelatedWork W2006385338 @default.
• W2044910514 hasRelatedWork W2029688276 @default.
• W2044910514 hasRelatedWork W2053778437 @default.
• W2044910514 hasRelatedWork W2100029565 @default.
• W2044910514 hasRelatedWork W2348495938 @default.
• W2044910514 hasRelatedWork W2380099415 @default.
• W2044910514 hasRelatedWork W2415963934 @default.

• next